Clinical Trial

Nivolumab for Treatment of Squamous Cell Carcinoma of the Skin

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
To determine the Objective Response Rate (ORR) of immunotherapy with Nivolumab (Group 1) and Nivolumab plus Relatlimab (Group 2) in patients with locally advanced/metastatic squamous cell carcinoma of the skin using Response Criteria in Solid Tumors Version 1.1 (RECIST1.1) per site assessment (Time Frame Group 2: From first dose up to 5 years)
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2019-12-17; most recent amendment 2024-04-17.
Status change: Active, Not Recruiting → Recruiting 2023-01-23
Status change: Recruiting → Active, Not Recruiting 2021-03-16
Trial Details
NCT Number NCT04204837
Lead Sponsor Salzburger Landeskliniken
Collaborators: Bristol-Myers Squibb
Conditions Squamous Cell Carcinoma of the Skin
Enrollment 61 participants
Start Date 2017-03-06
Primary Completion 2026-12 (estimated)
Study Completion 2027-12 (estimated)
Updated on ClinicalTrials.gov 2024-04-18